Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

Summary

to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST 4. changes in motor activity are associated with changes in language and overall results of the in MMST

Timeline

Start

2008-02

Primary completion

2009-12

Completion

2010-02

Drugs

Indications